Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | PREP | P48147 | 4/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911596 | 0.93 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL17483515 | 0.89 | CHRM2 (0.55) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL16253690 | 0.87 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL17716578 | 0.87 | CHRM2 (0.54) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL25010681 | 0.86 | CHRM2 (0.75) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL2123260 | 0.86 | CHRM2 (0.75) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL2299743 | 0.86 | CHRM2 (0.49) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL5243293 | 0.86 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL11993192 | 0.86 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL17716581 | 0.85 | CHRM2 (0.52) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022381-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170119778-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170119778-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-05-04 | — | — | US | disclosed |
| WO-2005000806-A2 | LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | CHRM2 4242/4885CHRM1 4248/4885CHRM3 4674/4885 |
| US-20170119778-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | CHRM2 4242/4885CHRM1 4248/4885CHRM3 4674/4885 |
| US-10022381-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | MTOR, RICTOR, PIK3CA | CHRM2 4242/4885CHRM1 4248/4885CHRM3 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.